Castle BiosciencesCSTL
About: Castle Biosciences Inc is a commercial-stage dermatological cancer company. It is focused on providing physicians and their patients with personalized, clinically actionable genomic information to make more accurate treatment decisions. The product portfolio of the company includes Cutaneous Melanoma, DecisionDx-Melanoma, DecisionDx-CMSeq, and DecisionDx-PRAME among others.
Employees: 710
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
844% more call options, than puts
Call options by funds: $8.7M | Put options by funds: $921K
153% more first-time investments, than exits
New positions opened: 43 | Existing positions closed: 17
52% more repeat investments, than reductions
Existing positions increased: 73 | Existing positions reduced: 48
33% more capital invested
Capital invested by funds: $553M [Q2] → $734M (+$181M) [Q3]
16% more funds holding
Funds holding: 158 [Q2] → 184 (+26) [Q3]
0.74% more ownership
Funds ownership: 92.1% [Q2] → 92.84% (+0.74%) [Q3]
0% more funds holding in top 10
Funds holding in top 10: 4 [Q2] → 4 (+0) [Q3]
Research analyst outlook
6 Wall Street Analysts provided 1 year price targets over the past 3 months
6 analyst ratings
Scotiabank Sung Ji Nam 45% 1-year accuracy 10 / 22 met price target | 52%upside $44 | Sector Outperform Maintained | 6 Nov 2024 |
Lake Street Thomas Flaten 33% 1-year accuracy 1 / 3 met price target | 39%upside $40 | Buy Maintained | 5 Nov 2024 |
Keybanc Paul Knight 38% 1-year accuracy 3 / 8 met price target | 25%upside $36 | Overweight Maintained | 5 Nov 2024 |
Baird Catherine Ramsey 50% 1-year accuracy 6 / 12 met price target | 35%upside $39 | Outperform Maintained | 5 Nov 2024 |
Canaccord Genuity Kyle Mikson 22% 1-year accuracy 2 / 9 met price target | 45%upside $42 | Buy Maintained | 29 Oct 2024 |
Financial journalist opinion
Based on 15 articles about CSTL published over the past 30 days
